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Tuberculosis is a highly contagious, infectious disease that kills about 1.8 million people 
annually. Current chemotherapeutic regimens are both inefficient and taxing to the patient. In 
addition, the disease has suboptimal treatment due to the rise of multidrug resistant strains of 
Mycobacterium tuberculosis (Mtb), the causative bacterial agent of tuberculosis. Therefore, we 
established a critical assay to identify novel drugs that interfere with specific Mtb virulence 
mechanisms. The mycobacterial protein fragment complementation (M-PFC) assay was 
developed to screen 725 compound drug panel to find candidate drugs that interfered with 
important virulence-causing protein interactions of Mtb. We targeted the EsxA-EsxB and EsxM-
EsxN interactions of the type VII secretion systems of Mtb. Our screen identified 46 small 
molecules that inhibited both virulence interactions, exhibiting nonspecific activity against a 
model cell line in vitro as well as seven hits specific to one of the two cell lines. In the future, we 
hope to retest the seven unique positive hits to confirm their ability to inhibit specific protein-
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Chapter 1: Literature Review 
Epidemiology 
Tuberculosis (TB) is a highly infectious, chronic airborne disease, that kills around 1.8 
million people annually, falling under one of the top ten causes of death worldwide (“Global”, 
2016). Despite current research and treatments, TB is the second leading cause of death in 
several regions, and one in three people carry the latent version of the disease worldwide. In 
2015 alone, 10.4 million people fell ill with TB (“Global”, 2016). After infection, TB can be 
present in either the active or latent form. If the immune system cannot control TB growth, then 
TB is considered active. If it is controlled, then TB is latent. But according to Centers for Disease 
Control and Prevention, 5-10% of people with the latent form of TB will develop the active form 
of TB in their lifetime (“Reported”, 2007). TB is highly concentrated in certain areas of the globe 
in which six countries account for 60% of the total 10.4 million: India leads in this count 
followed by Indonesia, China, Nigeria, Pakistan and South Africa.  
The probability of developing the disease is much higher for patients who are 
immunocompromised prior to their contact with tuberculosis, such as those infected with human 
immunodeficiency virus (HIV) as shown in Figure 1. Those infected with HIV are 20-30 times 
more likely to develop active TB; in 2013 alone, 360,000 people died from HIV associated TB 
(“Global”, 2016). Furthermore, the disease is highly contagious due to its mechanism of 
transmission. It is spread through aerosol transmission and primarily infects the pulmonary 
system. Aerosol droplets containing Mycobacterium tuberculosis (Mtb) enter the air 
passageways and travel through the respiratory tracts until they reach the alveoli of the lungs 
(“Reported”, 2007). Moreso, it is also possible for the bacteria to spread to other parts of the 
body; in extra-pulmonary tuberculosis, the causative agent disseminates to various organs 
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including the spine, kidneys, lymph glands, and gastrointestinal tract (“Global”, 2016; 
“Reported”, 2007).    
 




TB begins as Mtb-containing aerosol droplets reach the alveolar surface of the lungs after 
inhalation (Schluger, 1988). The host immune system then recruits macrophages to phagocytize 
the Mtb bacilli. The bacilli cause endosomal manipulation, resulting in maturation arrest, lack of 
acid pH, and ineffective phagolysosome formation. In a normal immune response, once the 
bacilli is engulfed, the phagosomes will fuse with the lysosomes, forming the phagolysosome. 
The digestive enzymes originally contained in the lysosome will eventually kill the bacilli (Flynn 
& Chan, 2001). Ineffective formation of the phagolysosome thus results in unchecked bacillary 
proliferation. The macrophages then travel to the nearby lymph nodes and present the antigen to 
CD4 T-cells, also known as helper T-cells (Müller et al., 1987). This activates a cascade of 
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protein pathways that cause activation of macrophages, which results in chemokine secretions 
(Chan, 1999). These signaling molecules cause monocyte recruitment and ultimately a 
granuloma forms at the site of infection. The center of the granuloma formed due to Mtb is 
characteristically described as having a soft cheese-like appearance, also known as caseous 
necrosis. This is due to the deterioration of tissue in the center of a granuloma, where the bacilli 
are exterminated (Bean, 1999). Additionally, virulent strains of Mtb have ways to inhibit 
apoptosis of macrophages. The anti-apoptotic characteristics of the bacilli are a key factor for 
virulence as they permit further growth of the bacteria within the host (Abdallah et al., 2011). 
This results in a primary infection of Mtb, which leads to the formation of the primary complex 
or localized caseation. Progression can result in fibrosis and calcification in affected organs. 
Dissemination of the bacteria occurs through the host’s blood and can affect either the lungs 
(pulmonary TB) or other organs (extrapulmonary TB).  
Once the host recovers from the primary infection, a secondary infection may occur 
immediately or the bacteria may remain latent for an indefinite period of time. A secondary 
infection occurs if remnants of the bacteria persist in open lesions or if Mtb is reintroduced 
through aerosols into the host. Because the host’s immune response is sensitized to Mtb, the 
tissue at the site of infection could experience caseating necrosis (Bean, 1999). Consequently, 
enough tissue in the lungs will erode so that the mycobacteria will spread throughout the 
airways, leading to a contaminated sputum and susceptibility for transmission (Smith, 2003). 
Additionally, Mtb can eventually gain access to both the pulmonary pathways from the heart as 
well as the systemic pathways, leading to lesions throughout the lungs and to additional organs. 
Mtb is well equipped to evade the adaptive immune response, so medicinal treatment is highly 




Current TB treatments are challenging for a variety of reasons. There is currently a four 
drug regimen prescribed for a period of 6-9 months that includes the administration of the first-
line drugs: isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and, ethambutol (EMB). 
Multidrug combination is important in TB treatment as each drug targets a different 
characteristic of TB virulence. These existing drugs and regimens are very enduring for infected 
patients because of their efficacy and time of therapy. Since the drugs must be able to penetrate 
human cells to reach the bacteria, which is actively designed to evading immune functions, the 
drugs are usually quite harsh on the human body. The regimen includes two months of intensive 
phase treatment and four to seven months of continuation phase treatment. The drug doses, long 
term treatment time frame, and economic cost of the 6-9 month intensive treatment make it 
especially difficult for individuals to overcome the disease (“Reported”, 2007). 
Vaccine Treatment and History 
In 1943, Selman Waksman developed streptomycin, the first known effective 
antimicrobial agent (Farmer & Keshavjee, 2012). Although streptomycin has clear bactericidal 
effects on Mtb, some strains of the bacteria developed antibiotic resistance. This led to the 
development of two new antimicrobial agents, thiacetazone and para-aminosalicylic acid. These 
agents hold a synergistic effect with streptomycin that leads to more effective treatments and a 
decreased resistance to antibiotics. The current first-line drugs, INH, RIF, PZA, and EMB, are 
part of a 6-month regimen used to eradicate the bacteria (Kaufmann, 2013). Since 1990, TB 
incidence rates (the ratio of new cases of the disease to the total population) have not fluctuated 
considerably, which is especially evident in developing countries where there have been no 
improvements in reducing incidence rates of the disease  (“Global”, 2016). 
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Currently, there is a safe, but limited vaccine called Bacille Calmette-Guerin (BCG), 
which was developed by Albert Calmette and Camille Guerin in the early 20th century 
(Kaufmann, 2013). This vaccine was first tested on a human subject in 1921 and still exists as 
the only licensed TB vaccine. It has been given to roughly 4 billion people worldwide to 
date,  mainly to individuals living in countries with a high prevalence of TB. The CDC notes that 
the BCG vaccine is generally not recommended for use in the United States because of its rather 
low effectiveness against adult pulmonary TB, the rather low incidence levels and risk of 
infection in the US, and the vaccine’s ability to interfere with the tuberculin skin test, the most 
common test to determine if an individual has TB (“BCG”, 2017). It is mainly given to children 
in countries with a high risk of infection as the vaccine has been proven to be effective against 
disseminated TB, and is thus usually administered soon after birth (Farmer & Keshavjee, 2012). 
However, it has been found that BCG provides insufficient protection against the disease in 
adults, rendering the need for newer, more efficient treatments. It does not prevent against 
reactivation of latent pulmonary infection into the active form, nor does it protect against 
primary infection (“Global”, 2017). Consequently, much of the efforts in the US to prevent and 
control the spread of TB is concentrated on the early detection and treatment of infected 
individuals with active TB, in addition to preventive therapy for those with latent TB in order to 
minimize and prevent the progression to its infectious active form. In terms of the reactivity of 
the BCG vaccine to the tuberculin skin test, it has the potential to induce a false positive result in 
vaccinated individuals  (“BCG”, 2017).  
Emergence of Multidrug Resistant Strains 
The TB epidemic is magnified by the emergence of multidrug resistant strains, that result 
from the failure to adhere to long term treatment (“Global”, 2016). Multidrug Resistant 
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Tuberculosis (MDR-TB) is resistant to INH and RIF and thus require a combination of second 
line drugs, aminoglycosides and fluoroquinolones (Dietrich & Doherty, 2009).  The treatment is 
more complicated as it is more expensive and lasts approximately 8 months. Currently, MDR-TB 
has spread to an estimated half-million cases worldwide. Extensively drug-resistant tuberculosis 
(XDR-TB) is resistant to INH, RIF, aminoglycosides, fluoroquinolones, and either amikacin, 
kanamycin, or capreomycin. These patients are left with limited treatment options and are at 
most risk. Currently, XDR-TB has been found in more than 84 countries, which is extremely 
concerning due to its high risk (Zumla, Nahid, & Cole, 2013).  The duration, adverse side effects, 
financial burden of current treatment and emergence of highly resistant Mtb strains calls for new 
drugs that provide both reduced toxicity and increased attenuating abilities.  
Structure of the Mtb Cell Membrane 
Mycobacteria possess a complex cellular envelope, consisting of several critical layers 
that contribute to its resistance to host cell defense mechanisms as shown in Figure 2. In 
comparison to gram-negative bacteria, gram-positive bacteria are generally considered more 
simple in terms of structure (Abdallah et al., 2007). Generally, the cellular envelope of a 
mycobacterium consists of a complex mycomembrane surrounding an inner membrane with an 
outer capsular layer. The mycomembrane is characterized by the presence of hydroxylated 
branched-chain fatty acids called mycolic acids that are covalently bonded to the cell-wall 
matrix, forming a low fluidity, hydrophobic layer (Abdallah et al., 2007). These mycolic acids 
are covalently intercalated with peptidoglycan and arabinogalactan. The outer capsular layer is 
characterized by the presence of different, non-covalently linked free lipids and proteins such as 
sulphatides, phenolic glycolipids, phthiocerol dimycocerosates, dimycolyltrehalose, and 
phosphatidylinositol mannosides that are specific to mycobacteria (Walters et al., 2006). The 
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combination of these layers all serve as protective barriers for survival in host phagosomes due 
to an increased tolerance to protective host factors such as antimicrobial peptides and oxidative 
radicals (Ates et al., 2015). In order for Mtb to exhibit its virulence, it uses a type VII secretion 
system (T7SS) to export proteins across the physical layers (Solomonson et al., 2015).  
 
Figure 2: Mtb Cell Envelope. Structure of the cell envelope of Mycobacterium tuberculosis  
 
Type VII Secretion Systems (T7SS) 
All mycobacterial species use T7SS to secrete proteins across their hydrophobic, 
impermeable cell envelope (Abdallah et al., 2007; Houben et al., 2014). Moreover, pathogenic 
mycobacteria require the T7SS to transport virulence factors through their protective and unique 
cell membranes into infected host cells (Daleke et al., 2012).  Pathogenic mycobacteria such as 
Mtb form a unique order of bacteria called Corynebacteriales characterized by the presence of 
mycolic acids within their cell wall (Houben et al., 2014). Corynebacteriales tend to be strong, 
resilient organisms due to their protective outer membrane (Houben et al., 2014).  This protective 
membrane restricts protein transport and is one of the main reasons why pathogenic 
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mycobacteria require T7SS (Houben et al., 2014). Once T7SS substrates are recognized in the 
cytosol, it is thought that they are targeted to the inner membrane and transported over the 
mycobacterial cell envelope (Houben et al., 2014). This transport is partially mediated by T7SS 
membrane components that form a translocation channel (Houben et al., 2014). There are still 
many unknowns about T7SS, including the method of substrate recognition, but it is known that 
substrates are normally secreted as folded dimers and have similar bundles of 4 alpha-helices 
followed by a secretion motif (Houben et al., 2014).   
Up to five of these T7SS can be encoded within the mycobacterial genome, with the 
number of genes and overall size of the loci varying significantly (Abdallah et al., 2007; Houben 
et al., 2014).  The five systems are named ESX-1 through ESX-5, in which three have been 
shown to be essential for virulence and viability of pathogenic species (Houben et al., 2014). The 
three loci, ESX-1, ESX-3, and ESX-5, are involved in the secretion of proteins while ESX-2 and 
ESX-4 are not known to be integral systems as neither have been proven to show active secretion 
of substrates (Houben et al., 2014). 
The first of the T7SS to be discovered was ESX-1 in Mtb (Stanley, 2003). The existence 
of the ESX-1 system was first evidenced in an experiment when the Mycobacterium bovis BCG 
vaccine for tuberculosis was complemented with the region of difference 1 (RD1) locus on Mtb 
(Abdallah et al., 2007).  When ESX-1 was discovered, it was shown to allow the secretion of two 
small culture filtrate proteins, originally called ESAT-6 and CFP-10 and now known as EsxA 
and EsxB, respectively (Houben et al., 2014). The proline-glutamic acid (PE) and proline-proline 
glutamic acid (PPE) proteins, which have been consistently associated with the ESX systems, are 
secreted by the ESX-1 and ESX-5 systems (Abdallah et al., 2007, Daleke et al., 2012). The PE 
and PPE proteins are structurally similar to the proteins EsxA and EsxB, containing the four-
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helix bundle in antiparallel fashion, and have a similar genetic organization (Houben et al., 
2014).  For the purposes of our study, we are focusing on ESX-1 and ESX-5 systems for their 
vital roles in the virulence of Mtb (Abdallah et al., 2007; Bottai et al., 2012; Houben et al., 2014). 
Inhibition of these two systems is predicted to result in an attenuated phenotype of Mtb. 
The ESX-1 Type VII Secretion System of Mycobacteria 
The genes for the T7SS ESX-1 are located on the Mtb genome at the RD1 locus (Guinn 
et al., 2004). RD1 is important for the virulence of Mtb as several mutants lacking this region, 
including BCG, experience attenuation in vitro and in vivo (Guinn et al., 2004). In addition to 
coding for the ESX-1 secretion system, RD1 codes for secreted factors important for virulence 
(Guinn et al., 2004; Pym et al., 2002). 
 To understand the role ESX-1 system plays in virulence it is important to understand its 
functions and what exactly is being secreted by the system. As previously stated, two of the 
proteins secreted by the ESX-1 system are the 6 kDA secreted antigen target, EsxA, and the 10 
kDa culture filtrate protein, EsxB (Simeone et al., 2009).  Through many experiments EsxA and 
EsxB were found to be key virulence factors (Abdallah et al., 2007; Brodin et al., 2005; Simeone 
et al., 2009). 
Wirth et al. in 2012 gave insights into the intracellular location of the ESX-1 system by 
fluorescently tagging the protein Rv3871 and examined its location in the cell in Msm. The 
protein was found to move to a distinct cell pole where there was a singular signal (Wirth et al., 
2012). The researchers used a different species of mycobacteria, but their results do give us 
insight into the possible location of the complex in Mtb, as well as a potential screening method 
that could identify attenuation (Wirth et al., 2012). Looking closer at the two main proteins 
secreted by the ESX-1 system, EsxA is a member of the WXG100 family of proteins that are 
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characterized by being approximately 100 amino acids in length and having tryptophan-variable 
residue-glycine as a conserved amino acid sequence (Brodin et al., 2005). EsxA and EsxB form a 
tight 1:1 heterodimeric complex, which is then secreted by Mtb through recognition of the C-
terminus on EsxB by ESX-1 (Brodin et al., 2005; Lou et al., 2017). Secretion of this complex is 
also dependent on EspA, EspC, and EspD (Stoop et al., 2012).  It should be noted that while 
other proteins known to be involved in the structure of ESX-1 localize to the cell pole, EsxA and 
EsxB does not localize to the cell pole with structural components (Wirth et al., 2012). 
More recently it has been found that the major virulence factors, EsxA and EsxB, are co-
secreted with two other factors, EspA and EspC (Lou et al., 2017).  Lou and colleagues (2017) 
found that EspC and EsxA associate in the cytoplasm and membrane, then EspC polymerizes 
during secretion from Mtb.  They concluded that EspC is either a component of the secretion 
system or has some effect on the function of ESX-1.  While the steps of ESX-1 secretion and the 
structure of the secretory apparatus are still unknown, it is known that most T7SS substrates 
carry a YxxxD motif as a general secretion signal (Daleke, et al., 2012; Lou et al., 2017).  EspC 
is one of these substrates, a small protein with a YxxxD motif.  Taking this into account with 
EspC’s co-secretion with EsxA, it is likely that the two proteins form a complex during 
translocation (Lou et al., 2017).  During secretion, EspC polymerizes into a filamentous structure 
that seems to span the capsule of Mtb and might represent a “secretion needle” of the ESX-1 
system (Ates & Brosch, 2016; Lou et al., 2017).   
Two other components of the ESX-1 structure are the soluble proteins EccB1 and EccD1 
and there have been recent discoveries in the structure of each (Wagner et al., 2016). EccB1 
consists of a central domain and four repeat domains that form a 2-fold symmetrical 
structure.  The repeating domains may play a role in anchoring the ESX-1 system due to their 
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similarity to a known binding protein (Wagner et al., 2016). EccD1, a cytoplasmic protein, has a 
“ubiquitin-like” fold and forms a dimer.  Knowing the structure to these ESX-1 components may 
help uncover ways to disrupt Mtb virulence in the future and would be vital to tuberculosis 
intervention strategies (Wagner et al., 2016). 
While investigating the mechanism of EsxA, Simeone and colleagues (2012) showed that 
Mtb lacking RD1 are confined to the phagosome. When transfected with RD1 on a plasmid, 
BCG (BCG::RD1) was able to escape host phagosomes and move into the cytosol (Simeone et 
al., 2012). This BCG mutant was successfully contained in host phagosomes when the esxA gene 
was knocked out of the bacterial chromosome, which indicates that EsxA is vital for the bacteria 
to escape into the cytosol (Simeone et al., 2012). After gaining access to the host cytosol, Mtb 
and BCG::RD1 proliferated unhindered within the macrophage and cause subsequent host cell 
necrosis. Necrosis is not ideal for the host as it allows for the rapid proliferation of virulent 
bacteria whereas programmed macrophage death does not allow for the same levels of Mtb 
proliferation (Simeone et al., 2012).  
It has been demonstrated that ESX-1 is vital for the virulence of Mtb and strains, such as 
BCG, that lack the presence of RD1 do not express the same virulence (Guinn et al., 2004). 
Virulence is conferred by the EsxAB complex, which is targeted and secreted by ESX-1 (Brodin 
et al., 2005). Secretion of EsxA allowed for Mtb phagosome escape and cause subsequent host 
cytotoxicity (Simeone et al., 2012). For these reasons, the ESX-1 secretion system and its 






The ESX-5 Type VII Secretion System of Mycobacteria. 
In contrast to ESX-1, ESX-5 is most recently evolved and restricted to slow-growing 
mycobacteria. This group of mycobacteria includes the major pathogenic species Mtb, 
Mycobacterium leprae, Mycobacterium ulceran, and Mycobacterium marinum (Mm) (Gey van 
Pittius et al., 2006). While ESX-5 has similar gene composition in comparison to the other 
T7SSs, it has functional variation. Generally, it is responsible for cell wall integrity and stability, 
host cell lysis and strong attenuation, using a duplicated four-gene region (ESX-5a) to transport 
secretory proteins and virulence factors (Shah & Briken, 2016). 
The ESX-5 T7SS is regulated at the transcriptional level by the Pst/Sen X3-RegX3 
system (Elliott and Tischler, 2016). Under phosphate-limiting conditions, the ESX-5 system 
becomes activated in response to this environmental stimulus and its mechanism is RegX3 
independent (Elliott & Tischler, 2016). Within the ESX-5 locus, there is a pair of esx genes that 
code for the EsxM and EsxN proteins, which dimerize in Mtb (EsxMN), are antigens found to 
induce CD4+ T-cell responses in various animal and human models. Upstream from the esxN 
gene, the ppe25-pe19 genes, named for their motifs near the N-terminus, code for associated PE 
and PPE proteins. The ESX-5 system is largely responsible for the secretion of these highly 
immunogenic, virulence-associated proteins, whose genes are found in slow-growing bacteria 
such as Mtb, coded by about 9% of its genome (Abdallah et al., 2007). This family of proteins is 
associated with virulence and cell well integrity (Bottai et al., 2012). The ESX ecc (esx 
conserved components) genes surrounding the ppe-pe-esx genes encode supporting membrane 




The functionality of the ESX-5 T7SS has been studied in various mycobacterial species. 
In Mm, the ESX-5 system plays a critical role in the modulation of cytokine responses by 
macrophages (Abdallah et al., 2008). The use of an ESX-5 knockout in Mm did not induce 
inflammasome activation or IL-1β secretion, indicating that ESX-5 is essential to these processes 
(Abdallah et al., 2011). While the ESX-5 secreted proteins are not required for the translocation 
of Mtb or Mm into host cells, the system does induce a caspase-independent cell death after 
translocation occurs, allowing infection of other cells (Abdallah et al., 2011). In a more recent 
study, the ESX-5 T7SS was found to play a substantial role in cell wall integrity, more 
specifically in the stability in the capsule layer of the cell wall. In Mm, ESX-5 and PPE10 
knockouts compromised the integrity of the capsular layer, which contains the substrates of the 
T7SS, and also leads to reduced surface hydrophobicity (Ates et al., 2016). In ESX-5 knockouts, 
PPE10 has been identified as the substrate responsible for the deficiency in the surface localized 
proteins of the capsular layer of pathogenic mycobacteria, in addition to morphological 
differences (Ates et al., 2016). In infected strains of Zebrafish, while ESX-5 mutant Mm led to 
slight attenuation in embryos, it also indicated highly increased virulence in infected adults, as 
seen by early granuloma formation and an increase in proinflammatory cytokines (Weerdenburg, 
2012). Additionally, studies have indicated that the ESX-5 system is also largely responsible for 
the uptake and use of hydrophobic carbon sources (Ates et al., 2015). 
To determine the role of the ESX-5 system in Mtb, the selected ESX-5 genes in the Mtb 
H37Rv strain, eccD5, eccA5, rv1794, esxM and ppe25-pe19, were inactivated with mutants, 
knocking out factors individually (Bottai et al., 2012). To determine the ability of the mutants to 
secrete EsxN in order to export PE/PPE proteins, the mutants were tested in vitro. To determine 
their effect on virulence, the ESX-5 mutants were tested in ex vivo and in vivo, using immune-
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deficient mice. While the deletion of rv1794 showed no significant difference from wild type 
secretion levels, the remaining four mutants relay strong defects in secretion of EsxN and the 
small hydrophilic PE/PPE protein, PPE41. PE and PPE proteins rely on the secretion of LipY, a 
substrate of the ESX-5 system in Mm (Daleke et al., 2011). PE and PPE proteins thus have a 
multitude of roles in virulence, both for its membrane structure and for its ability to attack the 
host. The immunogenicity of the PE and PPE proteins have been found to relay back to EccD5 
regulation (Sayes et al., 2012). Though the various ESX secretion systems do not complement 
each other, both ESX-1 and ESX-5 play significant roles in cell-to-cell migration and 
macrophage escape, suggesting that both T7SS operate independently in the cellular infection 
cycle (Abdallah et al., 2007).  
The PhoP and PhoR Two-component Regulatory System of Mtb 
The PhoP-PhoR (PhoPR) system is a two-component regulatory signal transduction 
system. Bacterial adaptation to host responses usually take the form of transcriptional activation 
of genes, whose products specifically help the bacterium live and cope with the surrounding 
environment. The two-component system contains an environmentally responsive histidine 
kinase and a response regulator, that is activated by the cognate histidine kinase. The aspect of 
the two component system plays a major role in the bacterial responses to altered environments 
(Stock et al., 2000). Therefore, this regulatory system of Mtb allows it to function and survive in 
harsh host cell environments, as well as evade the host cell response. 
In Mtb, this specific system controls around two percent of the genome and is thought to 
play a significant role in bacterial pathogenesis (Santos-Beneit, 2015). The importance of the 
system for Mtb survival is based on the production of complex lipids which play an essential role 
in creating the cell envelope for the bacterium. More than half of the genes that the system 
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regulates are annotated to encode proteins involved in lipid metabolism and secretion in addition 
to the creation of the components necessary for the cell envelope. 
Through knockout studies, the importance of the PhoPR system was established, where 
PhoP was inactivated in the Mtb strain H37Rv. Disruption of the system caused a marked 
attenuation of growth in macrophages and mice, establishing the importance of the presence of 
the system for growth of the bacterium. Strains where the two component system was inactivated 
made the bacterium more susceptible to a low magnesium environment, prohibiting the 
bacterium from proliferating and growing in such an environment. The PhoPR system is also 
essential for the biosynthesis of sulphatides and trehaloses. The cells from the knockout study 
did not contain these important complex lipid components of the cell envelope. Disruption of the 
genes that encoded the PhoPR two component system produced cells lacking in the complex 
lipids, making it more susceptible to host cell defense mechanisms (Walters et al., 2006). 
        The genes that were regulated in generating these complex lipids were found to be pks2 
and msl3, encoding enzymes for the biosynthesis of sulphatides and trehaloses. In the cells with 
the mutated phoP gene, there was reduced expression and transcription of pks2 and msl3, and 
therefore subsequent reduced production of the complex lipids. The cell envelope of the PhoP 
mutant lacked trehaloses and methyl branched fatty acids. The absence of these complex lipids 
could potentially compromise the permeability of the cell envelope, and lead to exposure of 
proteins normally protected by the Mtb capsule, and creating a greater sensitivity to the host cell 
response. PhoP also positively regulates two other genes involved in lipid metabolism, fbpA and 
lipF (Walters et al., 2006). Both of these genes have been speculated to function in generating 
lipases. These lipases have been thought to degrade host lipids during infection, making fatty 
acids available as building blocks for lipid biosynthesis for the bacterium (Walters et al., 2006). 
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        While the necessity of the two component system for creation and generation of the 
complex lipids was established, the necessity of a high magnesium environment when the mutant 
was introduced was still left undetermined. The researchers found that the Mtb phoP mutant 
required high levels of magnesium when the phoP gene was disturbed (Walters et al., 2006). 
While the researchers were able to state that the Mtb PhoPR system does not respond in sensing 
magnesium starvation, they hypothesized that the requirement of the mutant for high levels of 
magnesium could be a direct consequence of the structural alterations of the cell envelope. The 
absence of the sulphatides and trehalose components in the mutant may impair the integrity of 
the cell wall. Therefore, without these components, magnesium can function to stabilize the cell 
wall. When these components were missing in the mutant, high levels of magnesium fostered 
growth for the cells, whereas low levels of magnesium hindered proliferation (Walters et al., 
2006). 
        Without these components, the integrity of the bacterium as a whole becomes 
compromised, and the cell becomes more susceptible to the host cell defense mechanisms. Thus, 
PhoPR is important for virulence and the disruption of this interaction should produce an 
attenuated strain of Mtb (Ryndak et al., 2008). 
Repurposing Drugs for TB 
The long duration, high expense, high toxicity, and rise of MDR-TB and XDR-TB 
associated with current TB treatment brings to light the need for novel therapeutic drugs which 
can attenuate the disease in a stronger and more timely way (Zumla, Nahid, & Cole, 2013). 
Repurposed drugs offer a unique solution to the long-term and resource draining process that 
currently exists for drug approval (“Reported”, 2007). Today, a notable amount of drugs have 
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been repurposed for TB treatment: clofazimine, a drug previously used for leprosy, has been 
recently found to treat TB in mouse models (Verma et al., 2013).  
Repurposing drugs that were used for other causes previously and show usefulness in 
treating tuberculosis allows researchers to bypass the lengthy average of 12 years for discovery, 
preclinical development, and clinical development for FDA approval (“Reported”, 2007). Non-
conventional drug targets may also affect Mtb virulence systems that were not previously 
considered and thus provide insight to new methods of disruption. Current anti-TB drugs target 
central processes of the organism; however, administering repurposed drugs to possibly disrupt 
peripheral routes of virulence may be more efficient in eradicating the organism. Because 
virulence pathways are not targeted by anti-TB drugs, these pathways are currently not under 
survival pressures to mutate, so their vulnerability can be targeted for new treatments. 
Furthermore, in order to be of wide use, novel drugs should be compatible with current 
antiretroviral drugs used for HIV-AIDs patients, and this is more easily screened for when 
testing well established drugs. For this reason, NIH has created a Molecular Libraries Initiative 
which contains Molecular Libraries Small Molecule Repository for researchers to test the 
repurposing of clinically approved drugs.   
Advantages of Using Msm as a Model System 
The model organism chosen for our project was Msm. Mtb and Msm both come from the 
Mycobacterium genus. This homology allows for Mtb and Msm to share important characteristics 
such as biosynthetic pathways and cell membrane type (Tortoli, 2014). Conversely, it also allows 
for important differences to exist; most notably, Msm replicates more quickly and transforms 
more efficiently than Mtb (Michod, Bernstein, & Nedelcu, 2008). Most importantly, Msm allows 
for safer handling -- requiring Biosafety Level 2 (BSL-2) labs as opposed to Mtb, which requires 
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Biosafety Level 3 (BSL-3) labs (Singh et al., 2006). This is primarily due to the non-pathogenic 
nature of Msm in humans (Bohsali et al., 2010). These factors encouraged the selection of Msm 
as an optimal model system and carrier of relevant Mtb protein pairs. 
M-PFC Assay 
In this study, we sought to test a panel of repurposed drugs in disrupting important 
virulence interactions within the cell, namely type VII secretion systems and two-component 
regulatory signal transduction system, although testing for the latter system ended prematurely 
due to issues assembling the necessary assay for that system. In order to measure drug 
interaction, we required to use an assay that would give a clear indication of protein-protein 
interaction inhibition. The M-PFC assay was specifically designed to detect cytoplasmic and 
membrane-bound protein interactions within mycobacterium cells. In the assay, two proteins 
with known interactions in vivo were attached to mDHFR reporter fragments [F1,2] (expressed 
in pUAB300) and [F3] (expressed in pUAB400) as depicted in Figure 3. If [F1,2] and [F3] 
reassembled to a functional mDHFR, it conferred resistance against the antibiotic trimethoprim 
(TRIM) by allowing the bacteria to digest the antibiotic. [F1,2,3] refers to the polypeptide 
domains of the full enzyme mDHFR. There are several advantages of using the M-PFC assay, 
including its ability to detect a diverse range of protein-protein interactions. In previous tests, the 
M-PFC assay was successful in identifying interactions among proteins originating from Mtb 
(Bansal et al., 2017). Although this system can detect a diverse range of protein-protein 
interactions, it only attains a positive result, or successful coupling, between specific proteins 






Figure 3: Reconstitution of mDHFR in M-PFC System. Diagram depicting the reconstitution 
of mDHFR in the survival-based assay. Interacting proteins A&B allow for assembly of a 
functional mDHFR and, as a consequence, confer antibiotic resistance in the presence of TRIM. 
Non-interacting proteins A&C do not allow for mDHFR reconstitution and therefore prevent 











Reconstitution of mDHFR due to protein-protein interactions was simply monitored via 
survival-based assay. The M-PFC provides in-depth analyses about mechanisms such as protein 
modifications on protein-protein associations. Hence, the readout for in-depth analysis, named 
AB-TRIM, incorporates Alamar Blue. This compound has been used previously to assess the 
viability of mycobacteria in the presence of antimycobacterial compounds in 96-well formats. 
AB-TRIM is a colorimetric plate assay. The color of AB transitions from blue to pink at OD560 
depending on the level of growth, which is heavily dependent on the degree of reconstitution of 
mDHFR. Alamar Blue was the primary method of quantification of protein-protein interaction in 
Msm. Protein-protein interaction led to the reconstitution of the mDHFR, which led to the 
digestion of TRIM that allows for cell proliferation. The lack of protein-protein interaction meant 



















Chapter 2: Methodology 
The first step in analyzing the efficacy of the NIH drug panel on the model Msm mc2 155 
cell line involved cloning our genes of interest, which code for dimer-forming proteins, onto 
plasmids for use in the M-PFC assay. Using the assay, we evaluated protein-protein interactions 
within Msm in the presence of unique drugs through cellular growth levels. Quantification of our 
results was obtained through spectroscopy with Alamar Blue. 
Bacteria and Culture Conditions 
We transformed the DH5α strain of E. coli using pUAB300 and pUAB400 plasmids 
(Appendix A), which were then selected for on LB plates containing Hygromycin (final 
concentration of 50 µg/mL) or Kanamycin (final concentration of 150 µg/mL), respectively. 
These plasmids conferred resistance to their respective antibiotic, and colony growth was 
observed after overnight incubation at 37°C. Isolated colonies were subsequently picked and 
overnight liquid cultures were made with 3 mL of LB broth and either 3 µL of Kanamycin (50 
mg/mL stock) or 9 µL of Hygromycin (50 mg/mL stock). Frozen glycerol stocks of culture were 
made containing 15% glycerol (Mai et al., 2011; Singh et al., 2006). 
Following successful attainment of transformed E. coli, the plasmids were transferred to 
create Msm recombinant cells. Msm cells were initially grown in 7H9 medium with 10% 
Albumin Dextrose Catalase (ADC), 0.5% glycerol, and 0.05% Tween-80. The 7H9 medium was 
then supplemented with either 3µL Kanamycin (50 mg/mL stock) or 9µL of Hygromycin (50 
mg/mL stock). Similar to the E. coli protocol, the antibiotics in the media are specific to the 
transformed plasmids -- pUAB300 and 400 --  conferring selective resistance. The Msm cells 
were cultured to a target optical density of 600 (OD600) range of 0.5-1.0, which remained within 
the exponential growth phase. They were subsequently frozen at -80°C in 20% glycerol. The 
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cells were then thawed and incubated overnight in 7H9 broth without antibiotic present. The 
cells were diluted to target concentrations for the following assay (Mai et al., 2011; Singh et al., 
2006). 
In preparation for the M-PFC assay, 7H9 media containing Kanamycin or Hygromycin 
was supplemented with 50 µg/mL TRIM. Initially, cell concentrations in TRIM supplemented 
7H9 media were low during assays. To resolve this issue, overnights of transformed mc2 155 
cells were grown in TRIM supplemented 7H9 media to concentrate the amount of transformed 
cells in the frozen stocks (Mai et al., 2011; Singh et al., 2006). 
Cloning 
Constructing Desired Fusion Proteins for the M-PFC Assay to Test for Protein-Protein 
Interaction 
In order to perform the M-PFC assay, the pair of proteins suspected to interact will have 
to be expressed as a fusion protein with the murine dihydrofolate reductase (mDHFR) domains. 
This required each gene of a suspect protein, or insert, to be incorporated into a plasmid that held 
the gene for one of the mDHFR domains. After each insert was incorporated into its 
corresponding plasmid, both fusion plasmids expressing the interacting pair of proteins were 
transformed into our Msm cell line. In doing so, the Msm cell line had the ability to produce 




Figure 4: Cloning Flowchart. Flowchart depicting the sequence of cloning and transformation 
in creation of Msm recombinant cells. 
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To create these fusion plasmids displayed in Figure 5, the cloning method outlined in 
Figure 4 was employed. The inserts for esxA, esxB, esxM, esxN, phoP, and phoR were obtained 
through PCR.  The forward and reverse primers for each insert are listed in Figure 6. Annealing 
temperatures for esxA&B and esxM&N were 56°C, while the annealing temperature was 58°C 
for phoP&R. These inserts were then digested with the appropriate pairs of restriction enzymes 
listed in Figure 8 that would allow fusion with the appropriate plasmid. The M-PFC plasmids 
that contained the mDHFR domains, pUAB300 and pUAB400, were likewise digested with 
specific pairs of restriction enzymes to correspond with the given inserts. The pair of restriction 
enzymes created two unique sticky ends in the multiple cloning site of the circular M-PFC 
plasmid to form a linear plasmid. The inserts and plasmids of interest were isolated with gel 
electrophoresis by cutting the appropriate bands. The inserts were incorporated into the linear M-
PFC plasmid by treating the two parts with ligase (New England BioLab Inc., 2014). The inserts 
and vectors were ligated according to the following pairs: esxA with pUAB300, esxB with 
pUAB400, esxM with pUAB300, esxN with pUAB400, phoP with pUAB300, and phoR with 
pUAB400. The linear plasmids were treated with phosphatase to prevent self-ligations; 









Figure 5: Vector Maps of Empty Plasmids a) pUAB300 and b) pUAB400, with corresponding 
restriction sites (BamHI, PstI, HindIII, and HpaI for pUAB300; EcoRI, HindIII, and HpaI for pUAB400), 
antibiotic resistant genes (hygromycin for pUAB300; kanamycin for pUAB400), and fusion proteins 













esxB Forward GGGTGAATTCGGGAATGGCAGAGATGAAGACCGATG 
Reverse GGGAAGCTTGGGTCAGAAGCCCATTTGCGAGG 
esxM Forward GTTGCTGCAGAGGGATGGCCTCACGTTTTATGAC 
Reverse GTGAAGCTTGTTCTAGCTGCTCAGGATCTGC 
esxN Forward GGGTGAATTCGGGTATGACGATTAATTACCAGTTCGGG 
Reverse GAGAAGCTTGAATTAGGCCCAGCTGGAGCCGAC 
phoP Forward GGGGAAGCTTAGGGATGCGGAAAGGGGTTGAT 
Reverse TTTGTTAACGGGTCATCGAGGCTCCCGCAGTA 
phoR Forward GTTGAAGCTTGGGATGGCCAGACACCTTCGAG 
Reverse AAAGTTAACGAGTCAGGGCGGCCCTGGCAC 
Figure 6: PCR Primer Sequences. Sequences of primers used in PCR for each gene. 
Insert Empty Plasmid Restriction Enzymes 
esxA pUAB300 BamHI and HindIII 
esxB pUAB400 EcoRI and HindIII 
esxM pUAB300 PstI and HindIII 
esxN pUAB400 EcoRI and HindIII 
phoP pUAB300 HindIII and HpaI 
phoR pUAB400 HindIII and HpaI 
Figure 7: Restriction Enzymes. Restriction enzymes used for each insert and plasmid. 
 
After the plasmid vectors were formed, they were transformed into E. coli, which were 
grown on selectivity plates to ensure successful growth of only E. coli colonies with the desired 
plasmids. After an overnight growth of the selected colonies from the plates in liquid medium, 
plasmid purification was performed to isolate a large quantity of the desired plasmids. Then, the 
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success of the plasmid constructs was confirmed through gel electrophoresis and sequencing. 
Finally, electroporation of Msm cells was induced in order to create recombinant cells necessary 
for the M-PFC assay. The transformed bacteria were then grown on Hygromycin and Kanamycin 
plates to select for Msm recombinant cells that contain our plasmids of interest (New England 
BioLab Inc., 2014). 
Drug Screening to Determine Interference of Protein Interactions 
After desired Msm recombinant cells were isolated, the M-PFC assay was performed with 
our drug panel. The M-PFC assay measures protein-protein interactions by correlating it to cell 
growth in the presence of an antibiotic. The drug screen used triplicate wells of a 96-well plate 
consisting of the Msm recombinant cells and their fusion proteins at the minimum effective 
concentration, the antibiotic, TRIM, growth media, and the solvent, DMSO. Drugs that blocked 
protein-protein interactions prevented the cells from growing in TRIM, whereas drugs that did 
not interfere in the interaction resulted in cell death (Mai et al., 2011). Cell growth was noted as 
a negative result and cell death was noted as a positive result. Cells which survived and digested 
the Alamar Blue into a product that exhibited a pink color measured at 562 nm. Wells of interest 
were those that displayed a 75% reduction in absorbance relative to the solvent control. 
Origin of the Compound Library Source 
NIH’s Clinical Collection provided the drug library used in this experiment. This library 
includes plated arrays of 725 small molecules with known health benefits. Many of these drugs 
were originally designed for other diseases, but may have untapped potential in disrupting 
mycobacterial biological pathways. As these drugs have already passed clinical testing, they can 
be implemented more easily than new compounds. Ten plates of drugs are provided with the 
drug panel. The complete list of these compounds and their structures in each plate can be found 
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on the NIH Clinical Collection’s website. 10 µL of each drug were provided at 10 mM. The drug 
compounds were diluted to 200 µM concentration in water in new 96-well plates. 
Growth Assay 
Because optimal concentrations for Msm cells transformed with EsxA and EsxB 
(EsxAB), and EsxM and EsxN (EsxMN) are not established, an assay to assess growth was 
performed to identify these concentrations. The OD conversion at 600 nm for cell concen5tration 
is 1 OD = 3 𝗑 108 cells/mL.  The positive control was created through genetic recombination of 
pUAB100 and 200 plasmids with a gene encoding for a eukaryotic transcriptional activator 
protein, GCN4 (Hope & Struhl, 1987). This was produced in Msm and replicated for our positive 
control line. Ultimately, GCN4 promotes high protein-protein interaction and confers antibiotic 
resistance. Conversely, our negative control consisted of pUAB300 and 400 plasmids without 
additional gene inserts, which do not display cellular growth in the presence of TRIM due to the 
absence of interacting protein pairs. These controls, alongside wild type Msm cells, were 
prepared at 1.00𝗑106 cells/mL and 1.00 𝗑 105 cells/mL, and EsxAB and EsxMN cell lines were 
prepared at concentrations of 1.00 𝗑 107, 5.00 𝗑 106, 1.00 𝗑 106, 5.00 𝗑 105, 1.00 𝗑 105, 5.00 𝗑 104, 
1.00 𝗑 104, and 5.00 𝗑 103 cells/mL. A background negative control was prepared with 7H9 
liquid broth. The background negative control, positive control, negative control, wild type, and 
the transformants were dispensed on the 96-well plate as shown in Figure 9. The appropriate 
sample was added to each well, with each well having a final 1X TRIM content of 50 µg/mL. 
The plate was wrapped in foil and incubated for 24 hours before 10% by volume Alamar Blue 
was added to each well. The plate was again wrapped in foil and incubated from 6-8 hours. 
Afterwards, the plate was read with an Anthos 2010 microplate reader at 562 nm with a 




Figure 8: Colorimetric Plate Assay. Colorimetric plate assay demonstrating varying levels of cellular 
growth based on protein-protein interaction. Intensity of the pink color following TRIM treatment is 
proportional to the amount of TRIM resistant cells. esxA, esxB, esxM, and esxN are transformed into their 
respected empty plasmids and cells confer TRIM resistance. Positive control contains pUAB100 and 
pUAB200 interacting with a yeast protein. Negative control contains empty pUAB300 and pUAB400 
plasmids.  
 
Drug Screening Layout 
The OD were measured for overnight Msm cultures of EsxA-EsxB transformants, EsxM-
EsxN transformants, positive control, and negative control. Each culture was diluted to the 
optimal cell concentration determined by the growth assay, 5.55 𝗑 105 cells/mL. Figure 9 
presents the layout of the wells for positive control, negative control, negative background 
control, vehicle control (transformed cells with DMSO, the solvent for the drugs), and the drug 
tests on the 96-well plate. The positive control, negative control, vehicle control, and negative 
background control wells contained 180 µL of the appropriate 5.55 𝗑 105 cells/mL culture with 
20 µL of 5% DMSO to emulate the solvent conditions of the drugs. The drug test wells 
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contained 180 µL of the transformed cells at 5.55 𝗑 105 cells/mL culture with 20 µL of the 
diluted drugs in 5% DMSO. Final concentration of TRIM for all wells again was 50 µg/mL. The 
plate was wrapped in foil and incubated for 24 hours before 20 µL of Alamar Blue was added to 
all wells. The plate was again wrapped in foil and incubated from 6-8 hours. Afterwards, the 























Chapter 3: Results 
Cloning Results 
The PCR of the gene inserts (esxA, B, M, N) used the Mtb genomic DNA as a template. In 
order to create the plasmids to be used in the M-PFC assay, the M-PFC vectors and the inserts 
were ligated with their corresponding plasmids. The ligated plasmids were digested with 
restriction enzymes and placed on an agarose gel along with the empty M-PFC plasmids 
pUAB300 and 400 and the non-ligated inserts. The bands shown in Figure 9 show that the 
inserts were successfully replicated due to having the correct size. esxA has a length of 312 bp. 
esxB has a length of 329 bp. esxm has a length of 323 bp. esxN  has a length of 311 bp. Based on 
Figure 9, the insert bands on the gel were located below the 500 bp marker. Indicated in the top 
gel in the figure above are the successfully ligated esxA + pUAB300 and esxB + pUAB400 
plasmids, which should be similar in length as the original M-PFC vectors.  This indicates that 
the plasmids were successfully ligated. esxM + pUAB300 and esxN + pUAB400 were ligated 
with similar success. Unfortunately, the plasmids associated with phoP and phoR were not 
successfully ligated. The successfully constructed plasmids were then transformed into the Msm 





Figure 9: Image of the Gel Containing the esxA and esxB Inserts. 
The bands located below 500 bp indicate that the esxA and esxB 
inserts were successfully replicated (both esxA and esxB are about 
300 bp.) The bands of the ligated plasmid esxA + pUAB300 are 
located to the right of the esxA band, and the bands of the ligated 




Figure 10: Growth assay for EsxAB Msm transformants. Cells were grown for 
24 hours before Alamar Blue was added, and concentration was assessed using 
spectrophotometer at 562 nm with reference wavelength of 620 nm after 6 hours. 
From the plot, concentration of 5 𝗑 105 cells/mL will be used for screen.  
 
 
Figure 11: Growth assay for EsxMN Msm transformants. Cells were grown for 
24 hours before Alamar Blue was added, and concentration was assessed using 
spectrophotometer at 562 nm with reference wavelength of 620 nm after 6 hours. 




Growth assay data represented graphically with absorbance plotted against the 
logarithmic scale of the cell concentration. The optimal cell concentration was determined to be 
the point at the end of the exponential point of the graph where there is the largest change in 
absorbance with a relatively small change in concentration. Cells were allowed to grow for 24 
hours before Alamar Blue dye was added. Cells grew for an additional 6 hours before reading. 
For both cell lines in Msm, growth assay data appeared sigmoidal in shape, and the cell 
concentration that approached the top of the linear portion of the sigmoidal curve was 5 𝗑 105 
cells/mL. Repeated trials of the growth plate corroborated the results shown in the Figures 11 
and 12. Using this concentration will show the largest change in absorbance when inhibition 
occurs during screen.  
M-PFC Assay Drug Screening Results 







AB 2-Chloroadenosine 81% Adenosine receptor agonist 
AB Meclizine HCl 86% Histamine H1 antagonist 
MN Carmofur 76% Antineoplastic 
MN Cefdinir 90% 𝛽-lactam antibiotic, 
Cephalosporin 
MN 5-Fluorouracil 82% Antineoplastic 
MN Mefloquine HCl 87% Antimalarial quinoline 
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MN Ampicillin 95% 𝛽-lactam antibiotic 
 
Figure 12: Table of All Unique Positive Results for Both the EsxAB and EsxMN Cell Lines. The cell 
line corresponding to the unique hit, the compound name and compound classification is listed in each 
row. Drugs which tested positive for each cell line were considered to have native cytotoxic activity and 
were not considered unique positive results. 
 
Figure 13: Absorbance Data for Plate NCP004205 Tested Against the EsxMN Cell Line. This figure 
displays the results of the screen of the EsxMN cell line with compound plate NCP004205. Graph 
showing absorbance values of individual wells. The red line across the bar graph represents threshold for 
positive hits at absorbance of 0.089. Positive hits were taken as at least a 75% reduction in absorbance of 
the untreated cells, whose absorbance value is shown by the leftmost bar. 
 
While we chose to use a simple absorbance readout at 562 nm with a 620 nm reference, it 
should be noted that we used the same 75% reduction cutoff as previous work. In our case, we 
compared absorbance reduction as opposed to fluorescence reduction. Our NCP004205 plate in 
Figure 13 depicts a typical analysis of absorbance data. For simplicity, the other 19 graphs of 
our absorbance data were omitted and Figure 12 has been included as a model. While the 
tuberculosis necrotizing toxin (TNT)-immunity factor for TNT (IFT) pair cell line used by 
another group member previously produced 44 positive results with the same drug panel, our 
EsxAB cell line had 48 positive results and our EsxMN had 51. Of these, 46 were found to 
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overlap and deemed as non-specific growth inhibitors of Msm. Our nonspecific 46 results 
showed good agreement with the 44 found by the TNT-IFT cell line. The two unique hits for 
EsxAB and the five for EsxMN are shown in Figure 12 along with their percent growth 
inhibition values in their individual assays. We chose to focus on the unique hits for the 






















Chapter 4: Discussion 
The positive results shown in Figure 12 have yet to be evaluated to determine 
reproducibility as the screen was designed with the idea of being high-throughput and, as a 
result, data was only obtained in a single replicate for each compound for a screen. All of the 
compounds listed will be screened against both the EsxAB and EsxMN cell lines again in 
addition to being tested against our pUAB100 and 200 positive control cell line. Only if the drug 
tests positive for growth inhibition against one of the cell lines without being positive against the 
other two will it be considered a true positive. We will discuss all of the drugs in Figure 12 for 
their possibility as a unique inhibitor of the EsxAB or EsxMN interaction. 
Cefdinir and Ampicillin 
Cefdinir and Ampicillin both belong to the penicillin family of antibiotics, which contain 
the four-membered 𝛽-lactam ring and inhibit the cross-linking of peptidoglycan chains in the 
bacterial cell wall, causing lysis of the bacterium. Cefdinir falls under the sub-classification of 𝛽-
lactam antibiotics known as cephalosporins for originating from the fungus Acremonium. 
Cefdinir and Ampicillin have been tested against a variety of mycobacterial species to assess 
their viabilities for treating Mtb as well as M. avium. infections. Each of the drugs exhibited 
native cytotoxic activity against mycobacteria. Again, we have not had the opportunity to test 
these antibiotics against each of the cells lines, but we expect that upon testing again, we should 
see nonspecific cytotoxic activity. Also informing our hypothesis is that drugs such as penicillin 
and amoxicillin were included in this drug library but did not show specific killing activity for 






Carmofur and 5-Fluorouracil 
Carmofur and 5-fluorouracil are both modified nucleotides, which have been used for 
decades because of their antineoplastic activity. Both drugs show micromolar activity against 
Mtb. The best supported mechanism of action of these compounds in mycobacteria is their 
ability to inhibit the cell-wall biosynthesis. As both carmofur and 5-fluorouracil have shown to 
have native Mtb killing activity, we believe that both of these results will show as false positives 
when rescreened against both the positive control and EsxAB cell lines (Singh et al., 2015; 
Takenaka et al., 1995).  
Mefloquine 
Mefloquine is typically used in the treatment of chloroquine-sensitive P. falciparum 
malaria. As a derivative of the prototypical anti-malarial chloroquine, it inhibits the parasite’s 
ability to digest hemoglobin and crystalize heme. Both of these steps are critical for the ability of 
malaria to escape the erythrocyte and continue infecting red blood cells. Mefloquine has shown 
inherent inhibiting activity against Mtb in previous studies. While it is possible that the 
intracellular target of the drug is the EsxMN interaction, studies have shown that mefloquine is 
toxic to mycobacteria when in an in vivo mouse model and against free Mtb in vitro. Mefloquine 
has shown the remarkable ability to penetrate the host macrophage and phagosome in order to 
reach and kill the bacteria but the mechanism of action is most likely not related to inhibition of 
EsxMN. In addition, the recent study from our lab group specifically identified mefloquine as 
cytotoxic against Msm. We expect further testing this result will support our current hypothesis 






 2-chloroadenosine is commonly used as an adenosine-receptor agonist, which gives this 
compound large effects on both the nervous and immune systems. Previous work has evaluated 
2-chloroadenosine for its potential as an antimycobacterial agent. The study identified that the 
drug exerted growth inhibiting activity against both wild-type Mtb and BCG in liquid culture but 
not against Msm. Our positive result for our EsxAB could mean that we observed inhibition of 
our protein-protein interaction but, as previously explained, the EsxA-EsxB interaction is not 
vital for the viability of the bacterium in liquid culture. The apparent cytotoxicity exclusively 
against our cells is still of note as prior research has shown that we should not expect the 
observed activity. However, if 2-chloroadenosine does inhibit the EsxA-EsxB interaction leading 
to the death of our model cell line, its mechanism of action against different strains of Mtb must 
include another cellular target important to the vitality of the bacterium in free solution. While 
this result awaits duplication, we believe that part of 2-chloroadenosine’s action against Mtb may 
be related to inhibiting EsxAB dimer formation, although this activity is not naturally cytotoxic 
to the mycobacterium (Altaf et al., 2010).  
Meclizine 
Meclizine is typically used for the treatment of nausea, vertigo, and motion sickness in 
pregnant women and patients suffering from diseases that affect the vestibular apparatus. The 
drug functions as a histamine H1 antagonist and has not been evaluated for antimycobacterial 
activity to our knowledge. Our group lacks the software to predict why meclizine would inhibit 
the formation of the EsxAB dimer. EsxA-EsxB bind with an imidazole molecule in between 
them but meclizine does not bear resemblance to imidazole. While we are unable to confidently 
conjecture how meclizine may interfere with the EsxAB dimer, our preliminary results suggest 
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that this may be a novel agent for interfering with a vital virulence pathway of Mtb (Yerushalmy 
& Milkovich, 1965; Simons, 1989). 
Proof of Concept 
 Previous work by the Briken lab has established a screen similar to ours to test the same 
NIH Clinical Collection of compounds. However, in the past work, the readout was taken by 
utilizing the fluorescent nature of Alamar Blue while our study used a pure absorbance based 
readout. Figures 11 and 12 illustrate the ability of our dye to monitor cell growth by quantifying 
absorbance of light at 562 nm. In addition, previous work by Mai et. al. showed that a high-
throughput screening method could be established with the aid of robots. Our work was 
accomplished without the assistance of automation. Therefore, we have established a robust, 
high-throughput screening method to test potential inhibitors of the EsxAB and EsxMN 
interactions without automation and only utilizing a simple absorbance based readout. The 
present screen lacked access to known inhibitors of the protein-protein interactions which would 
be needed to confirm that the efficacy of this method. In addition to the potential inhibitors we 
have identified in our work, our screen possess the potential to be used as a high-throughput 
method for finding specific inhibitors of virulence pathways of Mycobacterium tuberculosis 
(Mai et al., 2011; Singh et al., 2006). 
Limitations 
The greatest limitation of our work was the inability to perform all trials in at least 
duplicate, which came about as a combination of factors. Lab work space was only conducive to 
performing trials as single replicates in a time-efficient manner. In addition, we had a limited 
amount of each compound provided by the NIH. However, our results are easy to verify by 
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performing the screen again or, in our case, testing specific, unique positive results to see if they 
do inhibit our protein-protein interaction.  
Future Implications 
 We believe that our studies have created two very important implications for future work. 
We have generated a high-throughput drug screen to test small molecules to see if they inhibit 
protein-protein interactions in Mtb without the use of automation or fluorescence. In addition, we 
have identified two molecules, meclizine and 2-chloroadenosine, that we believe may inhibit 
formation of the EsxAB dimer in Mtb. We hope to retest the results from our screen to identify if 

















Chapter 5: Conclusion 
 The first aim was to establish a high-throughput drug screen. Our screen, along with the 
other similar work from our lab have shown that the M-PFC system can be very robust in testing 
small molecules for their ability to inhibit protein-protein interactions of Mtb. In addition, we 
were able to investigate specific molecules which had positive results from our screen for their 
potential to inhibit the formation of the EsxAB and EsxMN dimers. The experiments we 
performed identified 46 molecules in the NIH Clinical Collection that possessed nonspecific 
growth inhibition, in that they affected both the EsxAB and EsxMN cell lines. Seven molecules 
were identified for their ability to selectively inhibit one of the two cell lines. We need to test 
these molecules again to confirm their specific activity but we believe that at least two of the 





















Appendix A: Protocols 
7H11 Plates 
This protocol makes roughly 40 plates. 
 
1. Pour 21 g of 7H11 mix into 900 mL of dH2O. 
2. Autoclave it on liquid cycle (takes ~ 1-2 hours).  
3. Take out the ADC from the the cell culture refrigerator and leave it on the bench so that it 
reaches room temperature. 
4. Wait for it to cool until cool enough to touch (leave it in the 55°C water block). 
-- make sure the following steps are done under the hood -- 
5. Add 5 mL of sterile 100% glycerol (10 mL if we use 50% glycerol). 
6. Add antibiotics (1 mL for 1 L for Kanamycin & Hygromycin). 
7. Add 100 mL of ADC (100mL for 1 L). 
8. Label the plates. 
9. Use the serological pipet to transfer 25 mL of the 7H11 media into the plate. 
10. Let it cool. 
11. When the plates solidify, put the plates in the 4°C fridge. 
 
DNA Gel Electrophoresis with TAE, 1% gel 
1. Load 5 µg of DNA ladder (GeneRuler 100 bp DNA Ladder) 
2. 10 µL of 6x DNA loading dye in 50 µL of PCR product 
3. Load all 60 µL of dye + PCR product into gel well. Separate each by one well so it is 
easier to cut/won’t mix together 
4. Set FB300 power unit to 120 V and run gel, bump up to 120 V to make it go faster (keep 
eye on blue dye moving). 
5. When placing gel into the tray, take off the tape you used to secure the gel in place. 
6. Visualize bands in dark room using tray. Clean first, wear long sleeve!  
7. Cut band between 1st and 2nd below fat band in middle used for orientation using razor 
blade. 
8. Put gel pieces with desired DNA in Eppendorf tubes and label them. 
9. Place in -20°C freezer in box. 
10. Dispose of gel waste in EtBr waste, dispose razor blades in sharps waste. 
 
Making Medium  
• Liquid LB Medium 
a. 25 g liquid LB powder 
b. 1 L H20 
c. Autoclave on fluid cycle 
• 20% TWEEN-80 
 . 4 mL 100% TWEEN-80 
a. 16 mL H20 
b. TWEEN-80 MUST be kept sterile 
c. Use autoclave water to save time from filtering 
• Stock 40% Dextrose 
 . 200 g dextrose 
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a. 500 mL H20 
b. Get stir bar ahead of time 
c. Stir immediately after mixing dextrose and H2O 
d. Dissolve dextrose in <500 mL and fill up to 500 mL after 
 
Autoclaving 
1. Each type of autoclaved agent has a different button (e.g. liquid for liquids) 
2. Stand towards the hinges when opening door to avoid burns 
3. Close tightly, but not so tightly so that it cannot be opened later 
4. Never screw caps on all the way 
5. Use autoclave tape 
6. Keep things with autoclave tape in Biohazard Safety Cabinet 
7. Steps in the autoclave room: 
a. Close 
b. Press yellow/orange button for Fluid Cycle 
c. Press “on” 
d. Be careful when opening the autoclave  
e. Put the setting on 20 min cycle and cool down 
f. Close the door tightly but not too tightly 
 
Innoculated Msm cultures in growth medium (wild type + positive control) 
1. Use glass beads to help with stirring (3-5 beads) 
a. using turbid solution, doing dilution of 1:10 so doubles every six hours 
2. 5 mL growth medium and 550 µl culture (for living cultures use filter tips) 
3. Pipette in vespine disinfectant and dispose in biohazard waste when done 
4. Incubate cultures in Msm incubator for 18 hours (overnight); no E. coli in that incubator 
5. Move to +4°C fridge 
 
Transformation of Competent E. coli Cells 
1. Remove E. coli competent cells from the -80°C freezer and thaw on ice. 
2. Into the cells into 50 µL of cells introduce 5 µL of DNA. Mix gently using the pipette tip. 
3. 2nd tube: just plasmid, no insert. 
4. Incubate on ice for 30 minutes. 
5. Transfer tube to 42°C heating block for 1 min to heat shock the cells. Put water in wells 
to hold heat better. 
6. Move the tube back on ice immediately for 2 mins. 
7. At the end of 2 mins, add 1mL of LB medium to the cells. Incubate in shaker in 37°C for 
1 hour. 
a. During this time prewarm the LB agar plates (with appropriate antibiotic) in the 37°C 
incubator. 
8. At the end of the 1-hour incubation, plate 50 µL of culture. Spin the remaining E. coli 
cells at 8000 rpm/1min. Discard the supernatant, leaving about 100 µL behind the tube. 
Resuspend the cells. 





Appendix B: All Positive Results for Both Cell Lines using the M-PFC System 
 




CLARITHROMYCIN Yes Yes 
TOSUFLOXACIN TOSILATE Yes Yes 
PAZUFLOXACIN Yes Yes 
KITASAMYCIN Yes Yes 
ENROFLOXACIN Yes Yes 
ETOPOSIDE Yes Yes 
IDARUBICIN HYDROCHLORIDE Yes Yes 
CLOFAZIMINE Yes Yes 
LEVOFLOXACIN Yes Yes 
TEGASEROD MALEATE Yes Yes 
RIFAPENTINE Yes Yes 
TRIFLUOPERAZINE HCl Yes Yes 
RIFABUTIN Yes Yes 
LINEZOLID Yes Yes 
RIFAXIMIN Yes Yes 
DOXORUBICIN HYDROCHLORIDE Yes Yes 
EPIRUBICIN HYDROCHLORIDE Yes Yes 
RUFLOXACIN MONOHYDROCHLORIDE Yes Yes 
PEFLOXACIN MESYLATE Yes Yes 
MOXIFLOXACIN HYDROCHLORIDE Yes Yes 
ETHAMOBUTOL Yes Yes 
LINCOMYCIN HCl Yes Yes 
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OFLOXACIN Yes Yes 
70458-96-7 Yes Yes 
RIFAPENTINE Yes Yes 
DAUNORUBICIN HYDROCHLORIDE Yes Yes 
MERCAPTOPURINE Yes Yes 
MINOCYCLINE HYDROCHLORIDE Yes Yes 
PYRIMETHAMINE Yes Yes 
DOXYCYCLINE Yes Yes 
BETAMETHASONE Yes Yes 
OXYTETRACYCLINE HYDROCHLORIDE Yes Yes 
DEMECLOCYLINE Yes Yes 
SULFISOXAZOLE Yes Yes 
CEFOXITIN  Yes Yes 
TETRACYCLINE Yes Yes 
SULFAMETHOXAZOLE Yes Yes 
CHLORAMPHENICOL Yes Yes 
SULFACETAMIDE Yes Yes 
AZITHROMYCIN Yes Yes 
MITOXANTRONE Yes Yes 
DAPSONE Yes Yes 
RIFAMPICIN Yes Yes 




ERYPED Yes Yes 
2-CHLOROADENOSINE Yes No 
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MECLIZINE HYDROCHLORIDE Yes No 
MEFLOQUINE HYDROCHLORIDE No Yes 
AMPICILLIN SODIUM No Yes 
5-FLUOROURACIL No Yes 
CARMOFUR No Yes 
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